Compare Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Sht-Term Inflation-Protected Sec Idx ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.45 (market cap $73.20B), while State Street SPDR S&P Biotech ETF trades at $149.99 (market cap $10.11B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 7.2× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| VTIP | XBI | |
|---|---|---|
Market Cap | $73.20B | $10.11B |
Volume | 2,511,360 | 12,903,266 |
52-Week High | $50.46 | $169.55 |
52-Week Low | $48.38 | $104.99 |
Typical Hold Time | 91 Days | 37 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTIP (Vanguard Short-Term Inflation-Protected Securities ETF) trades at $48.46, showing minimal daily movement with a 0.08% gain. Technical indicators present mixed signals with a bearish overall trend but bullish oscillators. The ETF focuses on short-duration TIPS to hedge inflation while minimizing interest rate sensitivity. Recent institutional buying activity includes NewEdge Advisors increasing their position by 45.5% in Q2 2026.
The ETF offers defensive positioning amid persistent inflation above the Fed's 2% target for 65 consecutive months. While providing inflation protection with reduced duration risk, VTIP faces headwinds from potential Fed policy shifts and competition from other TIPS vehicles. Real yields at multi-decade highs create attractive entry points for inflation-sensitive allocations.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
